Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Telix Pharmaceuticals LtdTLX · Entity 4101 | Group Chief Financial Officer | September 07, 2026 | September 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Telix Pharmaceuticals Ltd
Report date September 07, 2026 · Filed September 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 13,992 |
Reported balance
After 2026-09-07 transaction · row 1
1 source rowRow 1 · 2026-09-07 · Purchase · Acquired 2,071 · Balance 13,992 F1: Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026. F2: Purchase price is recorded in Australian Dollars. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026.
F2: Purchase price is recorded in Australian Dollars.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2026 Filed Sep 14, 2026 23:20 UTC | Telix Pharmaceuticals Ltd TLX · Entity 4101 | PurchaseOrdinary Shares | 2,071 | $9.66 | $19,997.58 |
DisclosureSEC source: 0001628280-26-061944 · wk-form4_1789428011.xml · nonDerivative · entry 1 Smith Darren Charlton · CIK 0002122447 · Group Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,992 F1 · shares: Represents shares purchased by the Reporting Person under the Employee Share Purchase Plan section of the Issuer's Equity Incentive Plan ("AU ESPP"), which shares were allocated on September 7, 2026, based on the Reporting Person's contributions to the AU ESPP from January 1, 2026 - June 30, 2026. F2 · price: Purchase price is recorded in Australian Dollars. Read SEC document |
| March 29, 2026 Filed Apr 1, 2026 23:14 UTC | Telix Pharmaceuticals Ltd TLX · Entity 4101 | Exercise / conversionShare Rights · Derivative | 1,111 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022909 · wk-form4_1775085272.xml · derivative · entry 2 Smith Darren Charlton · CIK 0002122447 · Group Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,111 shares Expires 2028-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The share rights (SRs) were granted on January 1, 2025 and became vested and exercisable on March 5, 2026. Read SEC document |
| March 29, 2026 Filed Apr 1, 2026 23:14 UTC | Telix Pharmaceuticals Ltd TLX · Entity 4101 | Exercise / conversionOrdinary Shares | 1,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022909 · wk-form4_1775085272.xml · nonDerivative · entry 1 Smith Darren Charlton · CIK 0002122447 · Group Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.